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Abstract
Background: Brd2 is a transcriptional regulator and belongs to BET family, a less characterized
novel class of bromodomain-containing proteins. Brd2 contains two tandem bromodomains (BD1
and BD2, 46% sequence identity) in the N-terminus and a conserved motif named ET (extra C-
terminal) domain at the C-terminus that is also present in some other bromodomain proteins. The
two bromodomains have been shown to bind the acetylated histone H4 and to be responsible for
mitotic retention on chromosomes, which is probably a distinctive feature of BET family proteins.
Although the crystal structure of Brd2 BD1 is reported, no structure features have been
characterized for Brd2 BD2 and its interaction with acetylated histones.
Results:  Here we report the solution structure of human Brd2 BD2 determined by NMR.
Although the overall fold resembles the bromodomains from other proteins, significant differences
can be found in loop regions, especially in the ZA loop in which a two amino acids insertion is
involved in an uncommon π-helix, termed πD. The helix πD forms a portion of the acetyl-lysine
binding site, which could be a structural characteristic of Brd2 BD2 and other BET bromodomains.
Unlike Brd2 BD1, BD2 is monomeric in solution. With NMR perturbation studies, we have mapped
the H4-AcK12 peptide binding interface on Brd2 BD2 and shown that the binding was with low
affinity (2.9 mM) and in fast exchange. Using NMR and mutational analysis, we identified several
residues important for the Brd2 BD2-H4-AcK12 peptide interaction and probed the potential
mechanism for the specific recognition of acetylated histone codes by Brd2 BD2.
Conclusion: Brd2 BD2 is monomeric in solution and dynamically interacts with H4-AcK12. The
additional secondary elements in the long ZA loop may be a common characteristic of BET
bromodomains. Surrounding the ligand-binding cavity, five aspartate residues form a negatively
charged collar that serves as a secondary binding site for H4-AcK12. We suggest that Brd2 BD1
and BD2 may possess distinctive roles and cooperate to regulate Brd2 functions. The structure
basis of Brd2 BD2 will help to further characterize the functions of Brd2 and its BET members.
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Background
Eukaryotic transcription is a highly regulated process.
Transcription activation in eukaryotes requires the modi-
fication of histones on enhancers and promoters [1,2].
Histone acetylation plays a major role in this modifica-
tion, and forms histone codes in combination with meth-
ylation, phosphorylation and ubiquitination [3-5]. One
potential postulate of histone codes is that defined pat-
terns of modification in histones can be recognized by
specific factors. Bromodomain, a conserved ~110 amino
acid module that is originally identified by sequence
alignment as a common motif among Drosophila Brahma,
female-sterile homeotic (fsh) and four other potential
transcription regulators [6-8], can recognize acetylation of
histones [9-13] and is thought to participate in decipher-
ing the histone codes [3,14-17]. Bromodomain-contain-
ing proteins have been classified into several distinct
subgroups: (i) histone acetyltransferases (HATs), includ-
ing GCN5, P/CAF and TAFII250; (ii) ATP-dependent chro-
matin-remodeling complexes, including Brahma, Swi2,
Snf2 and Brg1; (iii) the less-characterized BET (bromodo-
main and extra C-terminal domain) family, which is a
novel class of transcriptional regulators carrying two tan-
dem bromodomains and an ET domain [18]. Retention
on chromosomes during mitosis is likely a distinctive fea-
ture of the BET family [19-21], because proteins of other
bromodomain families are displaced from chromosomes
during mitosis [22,23]. There are four mammalian pro-
tein members of BET family: Brd2/Ring3 (also referred to
as Fsrg1), ORFX (Fsrg2), Brd4/HUNK1 (Fsrg4), Brdt
(Fsrg3).
Brd2 gene is initially identified as an open reading frame
localized to the class II major histocompatibility locus on
human chromosome 6p21.3 and is related to the Dro-
sophila gene female sterile homeotic (fsh) [24]. The homolo-
gous genes in mouse [25], frog [26], and zebrafish [27],
have been reported. Brd2 is a nuclear-localized serine-
threonine kinase that has elevated activity in human
leukemias [28,29]. It has been shown to synergistically
transactivate cell cycle regulatory genes, including cyclin
D1, cyclin A, cyclin E and dihydrofolate reductase (dhf), in
combination with Ras or MEKK through E2Fs [30]. A
murine homologue of Brd2 is contained in a mediator
transcription complex that involves homologues of the
yeast transcriptional regulators Med6, Med7, Rgr1, and
Srb7 [31]. Later on, Brd2 is reported to associate with a
transcription complex containing E2F-1, E2F-2, TBP and
chromatin remodeling machines [30,32,33], and to serve
as a bridge between E2F-1 and TBP [34]. Brd2 is also
reported to associate with mediator subunits cyclin-
dependent kinase 8 (Cdk8), thyroid receptor-associated
protein 220 (TRAP220), and the Pol II large subunit (Pol
II ls) [35]. Directed overexpression of Brd2 in mouse lym-
phocytes is found to develop B-cell lymphoma and leuke-
mia [36]. In addition, Brd2 can interact with latent
nuclear antigen (LANA) of Kaposi's sarcoma-associated
herpesvirus (KSHV/HHV-8) [37]. Taken together, these
reports indicate that Brd2 can serve as a transcription reg-
ulator and a contributing element in oncogenesis.
The bromodomains of Brd2 have been shown to selec-
tively bind to histone H4 tails acetylated at Lys12 (AcK12)
and to be responsible for mitotic retention on chromo-
somes [21]. The bromodomains are essential for tran-
scriptional activation of important E2F-responsive genes
by Brd2 through E2Fs. Bromodomain-deletion derivant
of Brd2 has a high level of autophosphorylation activity
and exhibites significant E2F-1 phosphorylation in vitro
compared with wild-type [32]. It is also reported that the
association of Brd2 with E2Fs, mediator components and
Pol II is dependent on the presence of and is stimulated by
acetylated histone H3 and H4 peptides [35]. The associa-
tion with E2Fs and specific interaction with acetylated his-
tones both establish anchor points for Brd2-containing
transcription complex to cyclin A promoter [33]. In addi-
tion, Brd4 (another BET member) also associates with
mitotic chromosomes, and tethers viral DNA to host's
mitotic chromosomes [20,38]. Brd4 interacts with P-TEFb
through its bromodomains and stimulates Pol II-depend-
ent transcription [39,40]. Hence the bromodomains and
their recognition of specific acetylated histones play
important roles in functions of BET family members. Bro-
modomains of the BET family differ substantially from
those of other families in amino acid sequence, despite
that they share conserved hydrophobic residues in the
hydrophobic core of the domain. Previous studies showed
that different bromodomains have different specificities
for binding to acetylated histones in living cells [21].
However, it is yet unknown the structural basis for Brd2
recognizing the specific acetylated histone code. Here, we
have determined the solution structure of the second bro-
modomain (BD2) of Brd2 by NMR and studied its bind-
ing properties to acetylated histone H4. Comparing this
structure with bromodomains from other proteins, signif-
icant differences are found in loop regions; specifically
some additional secondary structures exist in Brd2 BD2.
Using NMR titration experiments, the conserved hydro-
phobic cavity that is previously characterized in other bro-
modomains is found to serve as a binding site for histone
H4 acetylated at K12. Through mutational analysis, we
detected that the basic residues flanking the acetylated
lysine of histone H4 peptides, and some resides in loop
regions of Brd2 BD2 are important for their mutual recog-
nition. Our results provide further structural and func-
tional details aimed at revealing how Brd2 and other BET
members recognize specific acetylated histone codes and
thus impact transcription.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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Results
Structure description
Table 1 lists the structural statistics for the 20 structures
deposited in the Protein Data Bank [PDB: 2G4A]. A large,
negative Lennard-Jones potential energy was observed (-
360.86 ± 15.49 kcal mol-1), indicating good nonbonded
geometry of the structure. For the region from residue
Q302 to M406, the RMSD values to the mean structure
were 0.69Å for backbone atoms and 1.18 Å for all heavy
atoms [see Additional file 1]. The RMSD values for the
well-defined secondary structure elements were 0.58 and
1.07, respectively. In the ZA and BC loops, there was an
increasing level of disorder compared with the rigid sec-
ondary elements [see Additional file 1]. A stereoview of
the backbone superimposition of the final 20 structures
are shown in Figure 1A.
The tertiary structure of Brd2 BD2 consists of seven dis-
tinct helices and is totally 74% helical, which is consistent
with the circular dichroism prediction (data not shown).
Four of the α-helices, αZ (residues 302–315), αA (resi-
dues 349–358), αB (residues 364–381) and αC (residues
387–405), are arranged in closely compact, left-handed
bundle (Figure 1B) in an antiparallel manner. Crossing
angles between adjacent helices αZ and αA, αZ and αC are
~30°, while those between helices αA and αB, αB and αC
are ~10–20°. Most of the slowly exchanging NH protons
in 1H-2H exchange experiments were found within these
regions [see Additional file 2], which indicated that pro-
tection occurred most likely by formation of hydrogen
bonds here. In the long ZA loop between helices αZ and
αA, there are three additional short helices: α-helices αZ'
(residues 318–326) and αA' (residues 337–342), and an
uncommon π-helix, termed helix πD (residue 331–335).
The two helices αZ' and αA' are conserved in hsBRG1 and
GCN5 bromodomains, while helix πD is also found in
Brd2 BD1 [PDB: 1X0J] [41] and Brd4 BD2 [PDB: 2I8N].
The three helix structures were also confirmed by helix-
typical NOEs. Besides, helix αZ' was further affirmed by
1H-2H exchange experiments. The helix αZ' is orthogonal
to helices αZ and αA. Two hydrogen bonds are formed
between backbone carbonyl groups of F325 and Y326
with backbone amide groups of L349 and S350, respec-
tively, serving to cap the helix αA and help to anchor the
long ZA loop. A typical 'capping box' motif in N cap [42]
involving a hydrogen bond between OD1 of Asp (D348)
and NH of N3 (T351) was also found to cap the helix αA.
Both D348 and T351 are highly conserved in bromodo-
main sequences (Figure 2). Both helices αA' and πD may
be quite flexible or in 'structure breath' states for ligand
binding because helix αA' contacts only with helix αB
(Figure 1B), helix πD has no residue interacting directly
Table 1: Structural statistics for the selected 20 structures of Brd2 BD2a
Number of NMR restraints used in the structure calculation
Intra-residue 563
Sequential (|i-j| = 1) 573
Medium-range (|i-j|<5) 475
Long-range (|i-j|≥5) 355
Total NOE restraints 1966
Hydrogen bonds 49
Dihedral angle restraints 146
Lennard-Jones potential energy (kcal mol-1) -360.86 ± 15.49
RMSD from idealized covalent geometry
Bonds (Å) 0.0010 ± 0.00002
Angles (deg) 0.2878 ± 0.0016
Impropers (deg) 0.0972 ± 0.0038
RMSD from experimental restraints
Distance (Å) 0.0037 ± 0.0005
cdih (deg) 0.0436 ± 0.0214
Coordinate RMSD from mean (Å) residues 302 to 406
All backbone atoms 0.69
All heavy atoms 1.18
Secondary structure elementsb
All backbone atoms 0.58
All heavy atoms 1.07
Ramachandran plot (% residues)
Residues in most favored regions 87.0
Residues in additional allowed regions 10.3
Residues in generously allowed regions 2.5
Residues in disallowed regions 0.2
a None of the structure exhibits distance violations greater than 0.2 Å or dihedral angle violations greater than 2°.
b Residues Q302-S315, A319-Y326, H337-I342, L349-N358, A364-Y381, D387-K405.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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with the other helices, and few long-range NOEs and no
slow-exchange NH protons are observed in these regions
[43].
At the top of the protein (oriented as in Figure 1A), a
groove with a cavity at the bottom could be seen clearly on
the contact surface (Figure 1C). The cavity is lined by the
side-chains of residues (F325, V329, L334, L336, Y339,
M347, D348, M374, N377, C378, Y381, N382 and V388)
mainly from the ZA and BC loops (Figure 1D). Most of the
residues are hydrophobic and highly conserved in bromo-
domain sequences. From surface hydrophobic potential
and electrostatic potential mapping, the cavity is shown to
be hydrophobic and electroneutral in nature, suitable for
Structure and molecular contact surfaces of Brd2 BD2 Figure 1
Structure and molecular contact surfaces of Brd2 BD2. (A) Stereoview of the selected 20 structures of Brd2 BD2, 
superimposed on backbone atoms (N, Cα and C'). (B) Ribbon representation of the average, energy-minimized structure with 
the secondary structure elements highlighted. The helix nomenclature follows that of hsP/CAF bromodomain [9]. (C) Contact 
surface emphasized surface hydrophobic potential (left) and surface electrostatic potential (right) at the acetyl-lysine binding 
site. Yellow denotes hydrophobic potential; red negative potential; and blue positive potential. (D) A clear view of showing the 
conserved or type conserved side chains lined the hydrophobic cavity, and denoting the negative-charged collar formed by res-
idues D330, D338, D341, D385 and D387. A, B, C and D were produced with MOLMOL or PyMOL.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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hydrophobic contact mediating protein-peptide interac-
tions. Five aspartate residues (D330, D338, D341, D385
and D387) form a negatively charged collar surrounding
the edge of the hydrophobic cavity (Figure 1C and 1D). It
has been proposed that these acidic residues may play a
role in the specificity of bromodomain ligand binding
[11].
Structure comparison with other bromodomains
In spite that Brd2 BD2 share only 22–37% sequence iden-
tity with published bromodomain structures of hsGCN5,
scGCN5, hsCBP, hsP/CAF, hsBRG1, and of the double
bromodomain from TAFII250 [9,11-13,44-47], the overall
secondary elements and structural fold of Brd2 BD2
resemble those published bromodomains, as shown by
the backbone superposition of those structures on the
average, energy-minimized structure of Brd2 BD2 (Figure
2) and [see Additional file 3]. The pairwise backbone
RMSDs of those structures to Brd2 BD2 are between 1.6 to
2.6 Å. Recently, the structures of Brd2 BD1 and Brd4 BD2
(our lab unpublished data) have also been solved. Brd2
BD2 possesses high sequence identity and structural sim-
ilarities to its BET members (Figure 2), with pairwise back-
bone RMSDs between 1.4 to 1.8 Å. Figure 3 shows the
backbone superposition of Brd2 BD2 on Brd2 BD1. Our
results give further evidence that the unique structural
fold, especially the four-helix left-handed bundle involv-
ing helices αZ, αA, αB and αC, is highly conserved in the
bromodomain family.
The majority of structural deviations are localized in the
loop regions, particularly the long ZA loop. There are dif-
ferent additional secondary structures in the ZA loop,
including helices αZ', πD and αA' (Figure 2). All the bro-
modomain structures solved possess helix αA', and all
have helix αZ' except hsCBP. In the bromodomains of
hsGCN5, hsBRG1 and Brd2 BD1 the helix αZ' is a 310-
helix [11,41,46], while in Brd2 BD2 it is an α-helix
defined by typical α-helical NOE and hydrogen bond pat-
terns [see Additional file 2]. Another character of helix αZ'
in Brd2 BD2 is that it is longer compared with the others.
An uncommon π-helix, helix πD, is localized in the center
of the ZA loop of Brd2 BD2; relevant α-helices are present
in Brd2 BD1 and Brd4 BD2, but no corresponding helices
are present in other bromodomain structures (Figure 2). A
sequence feature of Brd2 BD2 and its BET family members
is that they have a long ZA loop and a two amino acids
insertion. Coincidently, the two amino acids insertion of
Brd2 BD2 (L334G335) is in the helix πD and contributes
to the hydrophobic groove, consequently it may play a
role in ligand selectivity. The helix πD could be a struc-
tural characteristic of Brd2 BD2 and other BET bromodo-
mains (Figure 2 and Figure 3). In the sequence of hsBRG1
bromodomain, there is also an insertion which forms a βZ
Sequence alignment of Brd2 BD2 Figure 2
Sequence alignment of Brd2 BD2. Sequence alignment of Brd2 BD2 with a selected number of Bromodomains including 
Brd2 BD1, Brd4 BD2, hsGCN5, scGCN5, hsCBP, hsP/CAF, hsBRG1 and the two components from TAFII250. The sequences 
were aligned based on the experimentally determined three-dimensional structures of these bromodomains, highlighted in 
green. The secondary structure of Brd2 BD2 is indicated above the alignment. Residues identical in all sequences are shown in 
red and residues conserved are coloured in blue and residues corresponding to βZ sheet (hsBRG1) and helix πD are repre-
sented in yellow. The two amino acids insertion is indicated by triangle symbols (▼ ).BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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sheet between helices αZ and αZ'[46]. Both the uncom-
mon helix πD in Brd2 BD2 and the βZ sheet in hsBRG1
support the view that bromodomains present in different
proteins must harbor sufficient structural diversities to
support specific recognition of acetylation codes.
Binding interface of H4-AcK12 peptide on Brd2 BD2
A previous study has demonstrated that Brd2 selectively
interacts with acetylated Lys 12 on histone H4 [21].
Accordingly, we have designed three histone tail peptides
(Table 2), H2B-AcK5, H4-AcK8 and H4-AcK12, to titrate
Brd2 BD2 using NMR experiments. The H4-AcK12 pep-
tide induced a number of distinct chemical shift perturba-
tions in the resonances of backbone amide groups of Brd2
BD2 in the 1H-15N HSQC spectrum (Figure 4). These
chemical shift changes increased gradually throughout the
titration that was taken to a maximum H4-AcK12 peptide:
Brd2 BD2 ratio of 10:1. These data indicate interactions
between Brd2 BD2 and H4-AcK12 peptide, and show that
the peptide and the protein are in fast exchange between
free and bound states on the NMR chemical shift times-
cale. Four most perturbed and not severely overlapped
residues, G335, L336, Y339 and Y381, were plotted in fig-
ure 4B, and the dissociation constant (KD) for H4-AcK12
peptide was estimated to be ~2.9 mM [48]. Unlike H4-
AcK12 peptide, H4-AcK8 peptide just slightly perturbed
the chemical shifts of several residues such as G335, L336
and Y339 at very high peptide concentrations and didn't
appear to interact significantly with Brd2 BD2. Addition
of H2B AcK5 peptide resulted in little, if any, chemical
shift perturbations of any protein residue, even at high
concentrations. Totally, our titration analysis showed that
Brd2 BD2 selectively bound to H4-AcK12, which was con-
sistent with a previous report [21]; further we acquired the
KD value for Brd2 BD2 binding to H4-AcK12 and deter-
mined this interaction to be dynamic in solution.
Additionally, our titration results made us to move for-
ward to map the binding interface of H4-AcK12 peptide
on Brd2 BD2 (Figure 5). Most residues experienced signif-
icant chemical shift changes upon addition of H4-AcK12
peptide were concentrated in the ZA and BC loop, and the
α-helical regions immediately flanking the BC loop.
Among these residues, D330, L334, G335, L336, H337,
D338, Y339, H340, D341, Y381 and A392 showed com-
bined chemical shift changes of more than the mean value
plus one standard deviation, and residues F325, A331,
H345, L373, M374, F375, Y379, N382, D385, H386,
D387, A390, M391, R393, K394, V398, K405 and M406
had combined chemical shift changes larger than mean
value. Many of the residues that were significantly dis-
turbed contribute to the hydrophobic pocket of Brd2 BD2
that serves as a primary binding surface for acetyl-lysine as
in the other bromodomains (Figure 1D) [9,11-13,44-47].
Mutational analysis
The complex structure of scGCN5 bromodomain with
H4-AcK16 peptide revealed that the major binding deter-
minant was the acetylated lysine and that the secondary
interaction came from the side chains at K+2 and K+3
positions [13]. The scGCN5 bromodomain only con-
tacted with acetylated Lys 16, His 18 (K+2) and Arg 19
(K+3). The corresponding residues in H4-AcK12 peptide
are unconserved Gly 14 (K+2) and Ala 15 (K+3) (Table 2).
We designed a set of mutations of the H4-AcK12 peptide
to determine which residues are critical for binding Brd2
BD2. NMR titrations of wild type Brd2 BD2 were per-
formed using H4-AcK12 mutant peptides, including H4-
L10A, H4-L10G, H4-A15G, H4-acid and the unacetylated
Backbone superposition of Brd2 BD2 and BD1 structures Figure 3
Backbone superposition of Brd2 BD2 and BD1 struc-
tures. Backbone superposition of the average, energy-mini-
mized structure of Brd2 BD2 (grey) with the crystal 
structure of Brd2 BD1 (pink) [PDB: 1X0J]. The figure was 
generated with MOLMOL.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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peptide H4-U (Table 2 and Figure 6). The H4-U and H4-
acid peptides did not disturb any residue amide reso-
nances of Brd2 BD2, indicating that acetylated H4 tail was
the preferred substrate and that those basic residues, Lys 8,
Lys 16 and Arg 17 of H4 tail, could play an important role
in the interactions. The H4-L10A and H4-L10G peptides
induced small but still significant resonance shifts. The
chemical shift changes induced by H4-A15G were like
those in response to H4-AcK12 at a low peptide: Brd2 BD2
ratio of less than 4:1. Strikingly, when H4-A15G peptide:
Brd2 BD2 ratio was large than 4:1, all the amide reso-
nances of Brd2 BD2 disappeared. This phenomenon was
confirmed by repeated titration experiments with two dif-
ferent protein concentrations (data not shown).
Further more, Brd2 BD2 mutants, including V329A,
L334A, L336A and N382A, were titrated with the H4-
AcK12 peptide, respectively. The integrity of Brd2 BD2
mutants were assessed by their 15N-HSQC spectra. Com-
pared with the 15N-HSQC spectrum of Brd2 BD2, mutants
V329A and N382A showed significant differences of
amide resonances for residues in the ZA and BC loop, and
some residues localized in the termini of helices αB and
αC; mutant L336A exhibited moderate differences for res-
idues in the ZA and BC loop; whereas mutant L334A just
slightly affected vicinal residues (Figure 7) and [see Addi-
tional file 4]. Both mutants V329A and N382A showed no
binding to H4-AcK12 peptide, which should be attributed
to severe disruption of the conformation of the binding
cavity. Mutants L334A and L336A have fewer residues per-
turbed upon H4-AcK12 binding than wild type Brd2 BD2,
and the perturbations are smaller. The unambiguous and
significantly perturbed residue G335 was followed during
titrations and plotted in figure 8.
Dynamic properties of Brd2 BD2
The longitudinal relaxation times (T1  ms), transverse
relaxation times (T2 ms) and ratio of NOE intensity are
recorded to probe the dynamic properties of Brd2 BD2.
The T2 relaxation times were obtained for 85% of the
backbone amide protons; the T1 relaxation times and 1H-
15N heteronuclear NOE values were obtained for 90% of
the backbone amide protons (Figure 9). The overall rota-
tional correlation time (τm) of the ~13.8-KD Brd2 BD2 is
10 ns (as estimated from the average values of T1/T2), sug-
gesting that BD2 is mainly monomeric in solution. The
average 1H-15N NOE value is 0.76 ± 0.09, indicating that
most of the regions of Brd2 BD2 are relatively rigid, corre-
sponding well with the narrow distribution of conformers
in the calculated ensemble. Some residues in the ZA and
BC loop have relatively lower 1H-15N NOE values and
these two loops construct the ligand-binding groove of
Brd2 BD2 (Figure 9) and [see Additional file 1].
Discussion
BET family is a less characterized novel class of bromodo-
main-containing proteins [18]. In the present work, we
have determined the solution structure of the second bro-
modomain of Brd2, which shares more sequence identity
with other BET bromodomains than with bromodomans
of other families (Figure 2). The structure of Brd2 BD2
consists of a previously characterized four-helix left-
handed bundle, with additional helices in ZA loop. Com-
pared with other published bromodomain structures,
extensive structural variations are found in loop regions
(ZA and BC loop); especially, in ZA loop there exists an
uncommon helix πD that is also present in BET family
members Brd2 BD1 and Brd4 BD2. We speculate that the
specific recognition of H4-AcK12 may involve this helix
πD. Recently published structure of hsBRG1 bromodo-
main reveals a βZ sheet insertion between helices αZ and
αZ'. The βZ sheet is proposed to have a role in orienting
an acetylated substrate by changing the flexibility of the
ZA loop [46]. The observations of the uncommon helix
πD insertion in Brd2 BD2 and the βZ sheet insertion in
hsBRG1 demonstrate that different bromodomains must
have sufficient structural diversities to support specific rec-
ognition of acetylation codes. More and more informa-
tion appears about the important functions of proteins in
the BET family; especially that it is observed that Brd2, as
well as Bdf1 and Brd4, remains mitotically associated with
chromatin [19-21]. Our study provides a structural basis
to further understand the functions of proteins in the BET
family.
Table 2: Peptides used for binding to Brd2 BD2
Name Sequence Derivation
H2B-AcK5 SDPA-AcK-SAPAPKK residues 1–12 of histone H2B
H4-AcK8 SGRGKGG-AcK-GLGK residues 1–12 of histone H4
H4-AcK12 GKGLG-AcK-GGAKR residues 7–17 of histone H4
H4-L10A GKGAG-AcK-GGAKR Leu 10 to Ala mutation of H4-AcK12
H4-L10G GKGGG-AcK-GGAKR Leu 10 to Gly mutation of H4-AcK12
H4-A15G GKGLG-AcK-GGGKR Ala 15 to Gly mutation of H4-AcK12
H4-acid GDGLG-AcK-GGADE Lys 8 to Asp, Lys 16 to Asp and Arg 17 to Glu mutations of H4-AcK12
H4-U GKGLGKGGAKR residues 7–17 of histone H4BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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Analysis of the interaction of Brd2 BD2 with H4-AcK12 peptide by NMR Figure 4
Analysis of the interaction of Brd2 BD2 with H4-AcK12 peptide by NMR. (A) Overlay of the 15N-HSQC spectra of 
Brd2 BD2 in free of H4-AcK12 peptide (red) and in the presence of H4-AcK12 peptide (cyan). Five of the most perturbed res-
idues (L334, G335, L336, Y339, and Y381) and the five negative-charged aspartate residues (D330, D338, D341, D385 and 
D387) were denoted. (B) Binding constant was determined by monitoring the combined chemical shift perturbations (∆δppm) 
of four most perturbed and not severely-overlapped residues (G335, L336, Y339 and Y381) as a function of concentrations of 
H4-AcK12 peptide.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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Binding interface of H4-AcK12 peptide on Brd2 BD2 Figure 5
Binding interface of H4-AcK12 peptide on Brd2 BD2. (A) A histogram view of combined chemical shift perturbations of 
Brd2 BD2 by addition of H4-AcK12 peptide. The mean value is denoted as a solid line and the mean value plus one standard 
deviation as a dash line. (B) A ribbon diagram view mapping the binding interface of H4-AcK12 peptide on Brd2 BD2. The res-
idues, whose combined chemical shift changes were more than the mean value plus one standard deviation and above the mean 
value, are colored in blue and cyan respectively. The figure B was generated in PyMOL.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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Consistent with a former study [21], our NMR titration
experiments show that Brd2 BD2 specifically binds to H4-
AcK12 peptide. We acquired the KD value (2.9 mM) for
this specific binding and determined the interaction to be
dynamic in solution. Brd2 BD2 binds to H4-AcK8 peptide
with much lower affinity and does not bind to H2B-AcK5
peptide or unacetylated peptide H4-U at all. While the full
length Brd2 can bind to H2B acetylated at K5/K12 [21],
Brd2 BD2 can not. One possibility is that Brd2 BD1 is
responsible for this interaction. The binding interface of
H4-AcK12 peptide on Brd2 BD2 is further identified by
NMR titration experiments, which is a conserved hydro-
phobic and electroneutral cavity with a negative-charged
collar formed by five aspartate residues (D330, D338,
D341, D385 and D387). These aspartate residues exhib-
ited significant chemical shift changes in Brd2 BD2 titra-
tion with H4-AcK12 peptide and served as a secondary
binding site as in hsGCN5 bromodomain [11]. The N-ter-
minal tail of histone H4 is positively charged; and coinci-
dently, when the positively charged residues (Lys 8, Lys 16
and Arg 17) flanking the acetylated lysine were mutated to
negatively charged residues, Brd2 BD2 no longer bound to
this peptide (Table 2 and Figure 6). When another flank-
ing residue Ala 15 on H4-AcK12 peptide was substituted
with glycine, it induced high aggregation of Brd2 BD2
with an unknown mechanism. Thus, the residue Ala 15
may also have a role in the specific recognition of H4-
AcK12 by Brd2 BD2. The complex structure of scGCN5
with H4-AcK16 peptide revealed a primary interaction
provided by acetylated lysine and a secondary interaction
NMR titrations of Brd2 BD2 with mutated histone H4 tails Figure 6
NMR titrations of Brd2 BD2 with mutated histone H4 tails. Brd2 BD2 was titrated with different H4-AcK12 peptide 
mutants, including H4-L10A, H4-L10G, H4-A15G, H4-acid and the unacetylated peptide H4-U. Combined chemical shift per-
turbation was calculated using the equation,  , and R = [peptide]/[bromodomain]. ∆∆∆ δδδ α ppm HN N N =+ () ( ) 22BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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Structural integrity analysis of Brd2 BD2 mutants Figure 7
Structural integrity analysis of Brd2 BD2 mutants. The integrity of Brd2 BD2 mutants were assessed by their 15N-
HSQC spectra. (A) Overlay of the 15N-HSQC spectra of Brd2 BD2 (red) and V329A (blue); (B) Overlay of the 15N-HSQC 
spectra of Brd2 BD2 (red) and N382A (green).BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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came from K+2 and K+3 positions [13]. Our result of Brd2
BD2 not binding to unacetylated peptide H4-U also soli-
date the notion that an acetylated lysine is a determinant
in bromodomain-ligand recognition. Residues Lys 8, Lys
16 and Arg 17 (corresponding to K-4, K+4 and K+5 posi-
tions) provide a secondary recognition, while the residue
Ala 15 (corresponding to K+3 position) may also be
involved in the interaction with Brd2 BD2. So the interac-
tion mode for Brd2 BD2 with H4-AcK12 peptide may be
different from that of scGCN5-H4-AcK16 complex, which
is further supported by the observation of large sequence
and structural variations in the ZA and BC loops between
Brd2 BD2 and scGCN5 [see Additional file 5].
The H4-AcK12 peptide binding pocket on Brd2 BD2 is
constructed of many conserved or type-conserved resides.
To determine which is crucial for H4-AcK12 recognition,
we designed a series of mutations in the binding cavity,
including V329A, Y339F, Y339A and N382A in respect
that all these corresponding residues in hsP/CAF, hsCBP
or scGCN5 bromodomains have extensive contacts with
their ligands. Especially, the highly conserved residue
N382 may be involved in orienting the acetylated Lys 12
as its corresponding residue N407 in scGCN5 [13].
Mutant N382A was constructed to examine its effect in
H4-AcK12 interaction. 15N-HSQC spectra revealed that
when the conserved residue V329 or N382 is mutated to
alanine, the Brd2 BD2 conformation is disrupted
throughout ZA and BC loops, even extending to the heli-
ces B and C for N382A mutant. Neither mutant V329A nor
mutant N382A binds to H4-AcK12 peptide. For Y339F
and Y339A mutants, the recombinant proteins have con-
verted into inclusion body when expressed in E. coli (data
not shown). Thus these highly conserved residues may be
more important in maintaining a proper conformation
for ligand recognition. On the other hand, L334A or
L336A mutant just mildly disturbs a few adjacent residues
and most likely doesn't affect the conformation of the
binding pocket. However, these two mutants bind to H4-
AcK12 with much lower affinities compared with wild
type Brd2 BD2. Mutation-induced function disruption
may be the main reason for L334A and L336A mutants
not binding to H4-AcK12 peptide. Both residues L334 and
L336 are localized in helix πD (residue 331–335), and
L334G335 forms a two amino acids insertion unique to
Brd2 BD2 and other BET members. Our results definitely
show that the two amino acids insertion and helix πD are
implicated in Brd2 BD2 and H4-Ack12 peptide interac-
tion. However, the complex structure of Brd2 BD2 with
H4 AcK12 peptide is needed to completely understand the
interaction mechanism.
The solution structure of Brd2 BD2 is monomeric,
whereas the crystal structure of Brd2 BD1 is determined to
be a homodimer [41]. No inter-molecular NOEs were
observed in Brd2 BD2, which was consistent with mono-
meric state as indicated by gel-filtration and GST-pull
down analysis (see methods). It is not surprising that Brd2
BD1 shares only 46% sequence identity with BD2 and the
dimeric residues are just partially conserved in BD2. In
fact, the equivalent BD1s or BD2s from different proteins
of BET family share higher homologies than the non-
equivalent BD1 and BD2 in the same protein. Although
both Brd2 BD1 and BD2 specifically recognize the same
acetylated histone H4 tail, it is reasonable to propose that
they play distinctive roles in Brd2 functions. In the Brd2
containing coactivator complex, BD1 may be a dimeric
module and interacts with TBP [33], while BD2 may
mainly serve to bind to acetylated histones. It is also prob-
able that Brd2 BD1 and BD2 interact with acetylated his-
tones in different context. And multi-bromodomains
could enhance the affinity for acetylated histones. An
intriguing question immediately rises and waits to
answer. How Brd2 BD1 and BD2 cooperate to regulate
Brd2 functions, and thus modulate its transcriptional acti-
vation effect?
Conclusion
Brd2 BD2 is monomeric in solution and interacts weakly
and dynamically but specifically with H4-AcK12. The
helix πD in the long ZA loop may be a common character-
istic of BET bromodomains. The conserved hydrophobic
cavity is found to serve as a primary binding site for H4-
AcK12 as in other bromodomains. A negatively charged
collar of the cavity serves as a secondary binding site for
H4-AcK12. Actually, the flanking basic residues on H4-
Plot of Brd2 BD2 mutants titrations with H4-AcK12 peptide Figure 8
Plot of Brd2 BD2 mutants titrations with H4-AcK12 
peptide. Brd2 BD2 mutants including V329A, L334A, L336A 
and N382A, were titrated with H4-AcK12 peptide. The 
doubtless and more significant perturbed residue G335 dur-
ing titrations was followed.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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AcK12 are important for their mutual recognition. Brd2
BD1 and BD2 may cooperate to regulate Brd2 functions.
The structure of Brd2 BD2 will help to further characterize
BET family members.
Methods
Cloning, expression and purification of Brd2
The DNA fragment encoding residues 301–408 corre-
sponding to the second bromodomain of Brd2 was ampli-
fied from human brain cDNA library (Clontech) by a
polymerase chain reaction (PCR) using the two primers
5'-CTCGAGATCTGGCATCTTGGCATAACGG-3' and 5'-
CATATGGAACAGTTAAAACATTGCAATG-3' (restriction
sites are underlined) designed based on the mRNA
sequence of Brd2 [GenBank: M80613]. The reaction prod-
uct (about 330 bp) was purified and then cloned into
pGEM-T vector (Promega). The positive clones were iden-
tified by restriction digest. Then the DNA fragment was
ligated into the NdeI/XhoI-cleaved plasmid pET22b(+)
(Novagen), yielding plasmid pET22b-BD2. The plasmid
pET22b-BD2 was then transformed into Escherichia coli
BL21 (DE3) host cells for expression. Uniformly labeled
recombinant Brd2 BD2 was produced using SV40
medium containing 0.5 g/l 99% 15N ammonium chloride
and 2.5 g/l 99% 13C-glucose as the sole nitrogen and car-
bon source, respectively. Recombinant Brd2 BD2 was
purified using Ni-chelating column (Qiagen). The puri-
fied recombinant Brd2 BD2 protein contains a C-terminal
His tag (LEHHHHHH), with the N-terminal Met cleaved
during expression (data from Mass spectrum). The purity
of recombinant Brd2 BD2 was confirmed by Tricine-SDS-
PAGE (15%, w/v) and the concentration was measured
with BCA kits (Pierce). The 15N-labeled and 13C,  15N-
labeled Brd2 BD2 were about 0.5–1.0 mM. All the sam-
ples for NMR contained 50 mM phosphate buffer (pH
5.8), 50 mM NaCl, 1 mM DTT, 1 mM EDTA in 90% H2O/
Plot of the longitudinal and transverse relaxation times and ratio of intensity of NOE Figure 9
Plot of the longitudinal and transverse relaxation times and ratio of intensity of NOE. The longitudinal (T1 ms) (A) 
and transverse relaxation times (T2 ms) (B) and ratio of intensity of NOE (C) are plotted as a function of residue number of 
Brd2 BD2. Only those residues of which 1H-15N cross-peaks are resolved enough to permit accurate measurements of their 
intensities are included.BMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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10% D2O or in 99.96% D2O. Brd2 BD2 mutants were
generated by conventional PCR method using pET22b-
BD2 plasmid as template. Mutants V329A, L334A, L336A
and N382A represented mutations of Val 329 to Ala, Leu
334 to Ala, Leu 336 to Ala and Asn 382 to Ala respectively.
The uniformly 15N-labled proteins of Brd2 BD2 mutants
were produced as described above. The integrity of Brd2
BD2 mutants were assessed by their 15N-HSQC spectra.
For GST fusion Brd2 BD2, the DNA fragment was cloned
into pGEX-4T (Amersham Bioscience) resulting plasmid
pGEX-BD2. The construct was also expressed in
Escherichia coli BL21 (DE3). The GST fusion protein was
purified using Sepharose 4B (Amersham Bioscience) and
following the protocols.
Characterization of Brd2 BD2 in solution
The state of purified recombinant His-tagged Brd2 BD2 in
solution was analyzed using gel filtration chromatogra-
phy and GST-pull down experiments. The gel filtration
analysis was performed with a ÄKTA FPLC instrument
(Amersham Biosciences) equipped with Hiload 16/60
Superdex 75 prep grade column. The purified His-tag
fusion Brd2 BD2 was loaded onto the column equili-
brated with a buffer containing 50 mM Tris and 500 mM
NaCl (pH7.8) and was eluted with the same buffer. The
molecular weight was calibrated with marker proteins
included Cytochrome C (MW 12300), Myoglobin (horse,
MW 17800), Chymotrypsinogen (MW, 25000), Albumin
(egg, MW 45000), Albumin (bovine serum, MW 67000).
In the analysis, Brd2 BD2 was eluted as a single peak,
demonstrating the homogeneity of the sample. The appar-
ent molecular weight of Brd2 BD2 was estimated to be 11
KD, corresponding well with the theoretic molecular
weight of Brd2 BD2 (13.8 KD) (data not shown).
In GST-pull down experiments, the purified recombinant
GST and GST-BD2 were immobilized on 200 µl Sepharose
4B beads. After washing four times (1 ml every time) with
GST binding buffer, the beads were then incubated with
excessive amount of His-tag fusion Brd2 BD2 in total vol-
ume of 1 ml at 4°C overnight. The beads were washed by
GST binding buffer supplemented with different concen-
trations of NaCl. Finally the proteins were eluted from
beads by boiling. All samples were analyzed on Tricine-
SDS-PAGE (15%, w/v) and stained with Coomassie bril-
liant blue. The GST-pull down experiments exhibited that
the His-tagged and GST-tagged Brd2 BD2 didn't associate
with each other in solution (data not shown). Accord-
ingly, the recombinant Brd2 BD2 was homogenous and
mainly monomeric in solution. Hence we moved forward
to perform NMR experiments of Brd2 BD2.
NMR spectroscopy and data processing
The NMR experiments were performed on a Bruker
DMX600 spectrometer with self-shielded z-axis gradients.
The following spectra were recorded at 298 K to obtain
backbone and side chain resonance assignments: 2D 1H,
15N-HSQC, 2D 1H, 13C-HSQC, 3D triple-resonance spec-
tra HNCO, HN(CA)CO, CBCA(CO)NH, CBCANH,
C(CO)NH-TOCSY, H(CCO)NH-TOCSY, 15N-TOCSY,
HBHA(CBCACO)NH, 2D CB(CC)HD-COSY (aromatics),
3D 15N-separted NOESY (mixing time 110 ms). The 13C/
15N-labeled sample was then lyophilized and dissolved in
99.96% D2O, which was followed immediately with
HSQC experiments to monitor the disappearance of NH
signals at 293 K. After all of the peaks vanished, 3D
HCCH-TOCSY, HCCH-COSY and 13C-separated NOESY
(mixing time 130 ms) were recorded on this sample at
298 K.
NMR data processing was carried out using NMRPipe and
NMRDraw software, and the data were analyzed with
SPARKY. All software was run on a Linux system. Linear
prediction was used to improve spectral resolution in the
indirect dimensions where constant-time acquisition was
used.
Experimental restraints and NMR structure determination
NMR distance restraints were collected from two different
NOESY spectra: 3D 15N-separated NOESY in H2O for
amide protons, 3D 13C-separated NOESY in D2O for
aliphatic protons. NOE restraints were grouped into four
distance ranges: strong, 1.8–3.0 Å and 1.8–3.5 Å;
medium, 1.8–4.0 Å and 1.8–4.5 Å; weak, 1.8–5.0 Å; and
very weak, 1.8–6.0 Å. Considering that the spin diffusion
effect could be serious for aliphatic protons, a more con-
servative distance estimation was used for the 3D 13C-sep-
arated NOESY; therefore, most medium-range and long-
range NOEs from this spectra were put into the weak or
very weak groups. The 1.8 Å lower limits were imposed
only implicitly by the van der Waals repulsion force. For
methyl protons, nonstereospecifically assigned methylene
protons, and aromatic ring protons, r -6 summation aver-
ages were applied. Based on the chemical shifts values, the
program CSI and TALOS were used to identify the second-
ary structure elements. The derived secondary structures
were converted into restraints on ϕ and ψ angles. Hydro-
gen bond restraints were obtained by identifying the slow
exchange amide protons mainly in the regular secondary
structures.
Structures were calculated using the program CNS v1.1,
employing a simulated annealing protocol for torsion
angle dynamics. For the initial rounds of structure calcu-
lations, only sequential, intraresidual, medium-range
NOEs, unambiguous long-range NOEs and dihedral angle
restraints were used. Later, all other long-range NOEs andBMC Structural Biology 2007, 7:57 http://www.biomedcentral.com/1472-6807/7/57
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hydrogen bonds were introduced in consecutive steps.
Simple impulsion nonbonded interactions were used dur-
ing structure calculation. At the final stage, 200 conform-
ers were calculated; of these, 20 conformers with the
lowest energy were selected. The coordinates of the 20
selected structures and the mean structure have been
deposited in the Protein Data Bank [PDB: 2G4A]. The
qualities of the structures were assessed with PROCHECK.
All residues are located in allowed regions on Ramachan-
dran plot apart from K217 due to paucity of inter-residual
NOEs. Being unassigned, the C-terminal His tag had no
NMR restraints, and they were excluded from structure
calculation.
Histone N-terminal tail peptides and NMR titration
The peptides of acetylated histone tails H2B-AcK5 (resi-
dues 1–12 of histone H2B, SDPA-AcK-SAPAPKK, where
AcK is an Nε-acetyl-lysine), H4-AcK8 (residues 1–12 of
histone H4, SGRGKGG-AcK-GLGK), H4-AcK12 (residues
7–17 of histone H4, GKGLG-AcK-GGAKR), H4-L10A (Leu
10 to Ala mutation of H4-AcK12, GKGAG-AcK-GGAKR),
H4-L10G (Leu 10 to Gly mutation of H4-AcK12, GKGGG-
AcK-GGAKR), H4-A15G (Ala 15 to Gly mutation of H4-
AcK12, GKGLG-AcK-GGGKR), H4-acid (Lys 8 to Asp, Lys
16 to Asp and Arg 17 to Glu mutations of H4-AcK12,
GDGLG-AcK-GGADE) and the unacetylated peptide H4-
U (residues 7–17 of histone H4, GKGLGKGGAKR) were
purchased from Sangon. All these compounds were used
without additional purification. For binding titrations,
the samples of 15N-labeled Brd2 BD2 and Brd2 BD2
mutants were prepared in phosphate buffer (pH 5.8) as
mentioned above, with the concentrations between 0.2
mM and 1.0 mM. Solutions of the peptides H2B-AcK5,
H4-AcK8, H4-AcK12, H4-L10A, H4-L10G, H4-A15G, H4-
U and H4-acid were prepared at concentrations between
55 mM and 100 mM, under identical buffer conditions.
The 1H and 15N resonance variations were followed at 298
K by collecting HSQC experiments. Combined chemical
shift perturbation was calculated using this equation,
, with a scaling factor
(αN) of 0.17.
15N relaxation experiments of Brd2 BD2
The 15N relaxation experiments were performed at 298 K
on a Bruker DMX500 spectrometer. 15N T1 and T2 relaxa-
tion rates with one second recycle delay were measured
with eight relaxation delays (21.2, 61.4, 142, 242, 363,
523, 804, and 1210 ms) and six relaxation delays (17.6,
35.2, 52.8, 70.4, 105.6, and 140.8 ms) respectively. The
spectra for measuring 1H-15N NOE were performed with a
two seconds relaxation delay followed by a three seconds
period of proton saturation. And the spectra acquired
without proton saturation employed a five seconds relax-
ation delay. The data analysis and exponential curve fit-
ting were processed using SPARKY.
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BD2. The thickness of the bars of sequential NOEs indicates the relative 
intensities of the corresponding cross-peaks in NOESY, and horizontal 
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